Which health wearable companies received funding?

This blog post has been written by the person who has mapped the health wearables funding market in a clean and beautiful presentation

The health wearables funding landscape has reached unprecedented momentum in 2024-2025, with smart rings, hormone monitoring, and AI-powered diagnostics attracting the largest investment rounds.

Oura's $200 million funding round stands as the largest wearable-specific raise, while corporate giants like Google, Apple, and Dexcom are actively acquiring and partnering with innovative startups across specialized niches from fertility tracking to chronic disease management.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which companies in the health wearable space received funding in 2024 and 2025 so far?

Finnish smart ring maker Oura dominated the funding landscape with its massive $200 million raise in 2024, establishing itself as the clear market leader in wearable health technology.

Blackrock Neurotech matched Oura's funding level with another $200 million round focused on neurotechnology applications, while India's Ultrahuman secured $35 million in Series B funding for their competing smart ring platform. These three companies represent the largest funding recipients in the sector during this period.

Early-stage companies are also attracting significant investment, with UK-based Level Zero Health raising €6.6 million for their groundbreaking continuous hormone monitoring device and Dutch company Sencure securing €7.9 million for wearable health chips. North American companies Strados Labs ($8.2 million for lung health monitoring) and Flosonics Medical (C$7.5 million for wearable ultrasound) round out the most notable funding recipients.

The funding activity extends beyond these headline deals to include specialized players in chronic disease management, fertility tracking, and elderly care monitoring, indicating broad investor confidence across multiple wearable health verticals.

How much total funding has been invested into health wearable startups in 2024 and 2025 to date?

The health wearables sector attracted $916 million specifically for smart rings and microneedle patches from January to October 2024, representing a focused subset of the broader digital health investment landscape.

Within the broader context, digital health startups including wearables raised $10.1 billion globally in 2024, while the medtech/devices/digital health/wearables sector recorded $4.0 billion in H1 2024 alone. Early-stage investment showed particular strength with $971 million across 106 first financing deals, up 34% from 2023.

Total medical device venture investment reached $7.5 billion across 421 deals throughout 2024, indicating robust investor appetite for hardware-focused health solutions. The funding distribution shows investors are particularly drawn to companies with proprietary sensor technology, AI-powered analytics, and clear paths to clinical validation.

Looking for growth forecasts without reading 60-page PDFs? Our slides give you just the essentials—beautifully presented.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which health wearable startup received the largest funding round recently, and how much was it?

Oura secured the largest health wearable funding round with $200 million in 2024, valuing the Finnish company at $5.2 billion and cementing its position as the dominant smart ring manufacturer globally.

Blackrock Neurotech tied for the largest round with its own $200 million raise, though their focus on neurotechnology represents a more specialized segment of the wearable health market. Both companies' funding rounds significantly exceeded typical Series B and C round sizes, which averaged $36 million and $45 million respectively in 2024.

These mega-rounds reflect investor confidence in companies that have achieved significant commercial traction and demonstrated clear paths to profitability. Oura's funding was particularly notable given the company's strong partnerships with healthcare systems and integration with major platforms like Dexcom for glucose monitoring.

The size of these rounds indicates that leading wearable health companies are transitioning from pure growth mode to preparing for potential public offerings or strategic acquisitions by larger technology and healthcare companies.

What kinds of technologies or breakthroughs in R&D are being backed by investors in this space?

Smart rings represent the most heavily funded technology category, with companies like Oura and Ultrahuman attracting hundreds of millions in investment for their comprehensive health monitoring capabilities including sleep tracking, heart rate variability, and recovery metrics.

Continuous hormone monitoring has emerged as a breakthrough technology attracting significant investment, particularly Level Zero Health's DNA-based, non-invasive hormone tracking system that eliminates the need for blood draws or saliva tests. This represents a major advancement in women's health and fertility monitoring.

AI-driven analytics platforms are receiving substantial backing for their ability to provide real-time diagnostics, personalized health insights, and predictive health risk modeling from wearable sensor data. Microneedle patches for non-invasive, continuous biomarker monitoring are also attracting investment as they promise to revolutionize how chronic conditions are managed.

Wireless biosensors for specialized applications like lung health monitoring, chronic disease management, and wearable ultrasound technology are gaining traction among investors who see potential for these devices to replace traditional medical monitoring equipment in clinical settings.

Who are the main investors or VC firms funding these health wearable startups?

Top-tier venture capital firms are leading the charge, with General Catalyst, 7wireVentures, Threshold Ventures, and Leaps by Bayer backing major deals like Transcarent's $126 million Series D round.

Asian sovereign wealth funds and strategic investors are playing an increasingly important role, particularly Temasek, Jazz Venture Partners, The Chernin Group, and Bedford Ridge Capital, which backed Oura's massive funding round. European investors like redalpine and HAX (SOSV) are actively funding breakthrough technologies such as Level Zero Health's hormone monitoring platform.

Specialized healthcare investors including Cottonwood Technology Fund, Bluegrass Ventures, and 819 Capital Partners are focusing on later-stage opportunities with companies that have demonstrated clinical validation and regulatory progress. Global mega-funds like General Atlantic, SoftBank Vision Fund, and Tiger Global Management are also allocating significant capital to the sector.

Corporate venture arms from major technology and pharmaceutical companies are increasingly active, with Boehringer Ingelheim Venture Fund, Leaps by Bayer, and other pharma CVCs seeking strategic partnerships alongside financial returns.

Which major tech or healthcare corporations are investing in or acquiring wearable health startups?

Google leads corporate involvement through its acquisition of Fitbit and ongoing strategic investments in wearable technology, while Apple continues expanding Apple Watch health capabilities through acquisitions like Tueo Health for asthma monitoring.

Healthcare giants are forming strategic partnerships rather than outright acquisitions, with Dexcom partnering with Oura to integrate glucose monitoring with smart ring technology. Johnson & Johnson's acquisition of Shockwave Medical demonstrates the broader medtech consolidation trend that's affecting wearable health companies.

Samsung has entered the market directly with the Samsung Ring while investing in advanced health-tracking wearables, competing head-to-head with established players. Northwestern Medicine, Dräger, and other healthcare institutions are providing both funding and clinical validation partnerships that de-risk investments for other stakeholders.

The corporate investment strategy focuses on acquiring specific technologies or capabilities rather than entire companies, allowing startups to maintain independence while gaining access to distribution channels and clinical expertise.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which startups have been funded that are targeting specific niches like sleep tracking, fertility, stress, chronic conditions, or elderly care?

Sleep tracking receives the most investment attention through smart ring companies, with Oura's $200 million and Ultrahuman's $35 million representing the largest funding rounds for comprehensive sleep and recovery monitoring platforms.

What are the typical deal structures or conditions investors are offering to health wearable startups?

Series A funding rounds in the wearables space have grown to an average of $25 million in 2024, while Series B rounds average $36 million, representing significant increases from previous years as investors demand more substantial traction before writing larger checks.

Early-stage startups typically allocate 20-30% of funding to R&D development and 10-15% to regulatory compliance and clinical validation costs, reflecting the highly regulated nature of health technology. Late-stage rounds face greater valuation scrutiny, with two-thirds of Series C and D rounds being flat or down in 2024.

Investors increasingly favor startups with established enterprise partnerships or healthcare system relationships, which can accelerate funding and reduce investment risk. Deal structures often include milestone-based funding tranches tied to regulatory approvals, clinical trial results, or commercial partnership agreements.

Venture debt is becoming more common for companies with proven revenue streams, as demonstrated by Flosonics Medical's C$7.5 million venture debt round, allowing companies to extend runway without diluting equity ownership.

Which geographies are attracting the most investment in health wearables—US, Europe, Asia, or emerging markets?

North America dominates investment volume and market share, capturing approximately 39-45% of global health wearables funding, driven by strong venture capital ecosystems in Silicon Valley, Boston, and Seattle.

Europe shows strong growth momentum, particularly in the UK, Germany, and Nordic countries, with London emerging as a leading hub for healthtech investment and companies like Oura (Finland) and Level Zero Health (UK) securing major funding rounds. The European market benefits from strong regulatory frameworks and government support for health innovation.

Asia-Pacific represents the fastest-growing region for health wearables investment, with India (Ultrahuman), China, and Japan seeing rapid adoption and increasing venture capital interest. The region's large population base and growing middle class create massive market opportunities for scalable health solutions.

Emerging markets in Latin America and Middle East/Africa remain smaller but are attracting targeted investments in locally-focused startups that address region-specific health challenges and regulatory environments.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What stage are most of these companies in—seed, Series A, Series B, or later-stage?

Early-stage companies (seed and Series A) remain active in the funding landscape, particularly for startups with strong intellectual property or breakthrough sensor technologies, as evidenced by the 34% increase in first financings to $971 million across 106 deals in 2024.

Series B and later-stage companies receive fewer but larger funding rounds, with investors demanding stronger clinical validation and commercialization progress before committing capital. Companies like Oura and Blackrock Neurotech represent the later-stage category with their $200 million rounds.

Pre-seed and seed companies like Level Zero Health (€6.6 million pre-seed) demonstrate that breakthrough technologies can still attract significant early-stage investment, particularly in emerging categories like continuous hormone monitoring. The funding landscape shows a clear bifurcation between early-stage innovation and later-stage scale.

Most successful companies are transitioning from Series A to Series B within 18-24 months, driven by accelerated product development cycles and faster paths to clinical validation through partnerships with healthcare institutions.

Are there signs of consolidation or IPO interest among these funded health wearable companies?

Merger and acquisition activity is accelerating rapidly, with 27 medtech and wearables M&A deals totaling $16.5 billion in H1 2024 alone, indicating significant consolidation pressure across the sector.

Leading companies like Oura and Whoop are reportedly preparing for IPO opportunities, though most exits continue to occur through strategic acquisitions by larger technology and healthcare companies. Distressed M&A activity is rising as weaker startups seek exits amid challenging funding conditions.

Corporate buyers are particularly active, with companies like Apple acquiring specialized capabilities (Tueo Health for asthma monitoring) and strategic partnerships becoming more common than outright acquisitions. The IPO pipeline remains limited but shows signs of revival with companies that have achieved substantial revenue scale and clear paths to profitability.

Market consolidation is creating opportunities for well-funded companies to acquire complementary technologies and expand their platform capabilities, as seen in partnerships between Oura and Dexcom for integrated glucose and wellness monitoring.

What funding trends or forecasts are emerging for health wearables going into 2026?

AI integration represents the strongest funding trend, with startups leveraging artificial intelligence for diagnostics, personalized health insights, and predictive analytics attracting larger funding rounds and higher valuations from investors seeking scalable technology platforms.

Women's health and femtech applications are emerging as a hot investment category, with continuous hormone monitoring, fertility tracking, and menopause management solutions attracting significant venture capital interest. Next-generation sensors including microneedle patches and non-invasive biomarker tracking are receiving substantial investment for their potential to revolutionize chronic disease management.

Elderly care and chronic disease management solutions are gaining investor traction, particularly in Asia-Pacific and North America, driven by aging populations and healthcare cost pressures. Cross-border investment activity is increasing, with more deals involving Asian and European investors collaborating with North American startups.

Investors are becoming more selective, favoring startups with clinical validation, regulatory progress, and scalable business models over pure technology plays. Corporate venture capital is returning to the sector as established healthcare and technology companies seek strategic partnerships and acquisition targets.

Need to pitch or understand this niche fast? Grab our ready-to-use presentations that explain the essentials in minutes.

Conclusion

Sources

1. Rise TKU - Health Industry VC Funded Companies 2025 Report
2. DealForma - Medtech Devices Digital Health Wearables M&A Q2 2024
3. Nocturnal PD - 2024 Medical Device Investment Data
4. Rock Health - Healthcare Innovation at the Turn of 2025
5. Mass Device - Biggest Medtech Fundraising Rounds 2024
6. Tech Funding News - Wearable Technology
7. Galen Growth - Q1 2024 Digital Health Insights
8. EU Startups - Level Zero Health Funding
9. TechCrunch - Level Zero Health Banks $6.9M
10. 819 Capital - Sencure Secures €7.9M
11. StartUp Health - Flosonics Medical Secures C$7.5M
12. Exploding Topics - Wearable Startups